Introduction The imaging features of unresectable hepatic malignancies in patients who underwent radiofrequency ablation (RFA) in combination with lyso-thermosensitive liposomal doxorubicin (LTLD) were determined. Materials and Methods A phase I dose escalation study combining RFA with LTLD was performed with peri-and post-procedural CT and MRI. Imaging features were analyzed and measured in terms of ablative zone size and surrounding penumbra size. The dynamic imaging appearance was described qualitatively immediately following the procedure and at 1-month follow-up. The control group receiving liver RFA without LTLD was compared to the study group in terms of imaging features and post-ablative zone size dynamics at follow-up. Results Post-treatment scans of hepatic lesions treated with RFA and LTLD have distinctive imaging characteristics when compared to those treated with RFA alone. The addition of LTLD resulted in a regular or smooth enhancing rim on T1W MRI which often correlated with increased attenuation on CT. The LTLD-treated ablation zones were stable or enlarged at follow-up four weeks later in 69 % of study subjects as opposed to conventional RFA where the ablation zone underwent involution compared to imaging acquired immediately after the procedure. Conclusion The imaging features following RFA with LTLD were different from those after standard RFA and can mimic residual or recurrent tumor. Knowledge of the subtle findings between the two groups can help avoid misinterpretation and proper identification of treatment failure in this setting. Increased size of the LTLD-treated ablation zone after RFA suggests the ongoing drug-induced biological effects.
Introduction
Radiofrequency ablation (RFA) is a widely accepted treatment of choice for unresectable hepatic neoplasms and intrahepatic distant recurrences [1] , but may be limited by the size of the lesion that can be treated. Currently, large lesions ([3 cm in diameter) suffer from unacceptably high failure rates [2] [3] [4] [5] [6] . Although surgical resection remains the gold standard for HCC [7] [8] [9] , only approximately 20 % of patients are candidates for this therapy [10] . Expanding the indications for local hepatic RFA could potentially result in more patients benefitting from this locoregional therapy with less untreated microscopic disease in the treatment margins [4] .
Heat-deployed chemotherapy applied locally in the periphery of the thermal lesion could provide more effective therapy through concentrating the drug in the area of highest treatment failure. Low temperature-sensitive liposomes that release doxorubicin at temperatures greater than 39.5°C have been developed (ThermoDox Ò , Celsion Corp, Columbia, MD). In vitro models using lyso-thermosensitive liposomal doxorubicin (LTLD) have shown that doxorubicin is deposited at the highest concentrations within 1 cm outside the ablation zone [11] . The dual benefits of this approach consist of reducing systemic toxicity of the chemotherapeutic agent while exposing the tumor site, particularly the tumor or treatment margin, to a higher concentration gradient of the drug.
A Phase I clinical trial evaluated the safety of LTLD administration, in conjunction with RFA, in unresectable hepatic malignancies and determined the maximum tolerated dose (MTD) of the LTLD to be 50 mg/m 2 [12] . A recently completed randomized controlled phase III clinical trial used this LTLD and RFA in combination to treat HCC tumors 3-7 cm with high local failure rates from RFA. This trial was considered to be a Priority Clinical Trial for HCC at the National Cancer Institute's Clinical Trials Planning Meeting [13] .
Post-treatment imaging from the Phase I clinical trial revealed characteristics unlike those of typical post-ablative lesions [14] . The CT features of hepatic lesions in the period following RFA enhanced by LTLD are described, as Response Evaluation Criteria in Solid Tumors and World Health Organization criteria are not applicable for ablated lesions [15] . The purpose of this analysis is to characterize these atypical imaging findings which may assist radiologists in determining a more accurate assessment of treatment response after this dual therapy. As the future use of RFA and LTLD increases, diagnostic and interventional radiologists should be familiar of the imaging features following this combined locoregional therapy in order to avoid misinterpretation of drug effects for residual or recurrent tumor.
Typical CT Imaging Features of RFA
On contrast-enhanced CT, the treated area displays nonenhancement on both the arterial and portal venous phase, occasionally surrounded by a penumbra which is a narrow, concentric, smooth rim of contrast enhancement that arises as a benign response to thermal injury [16] . Usually, this benign peri-tumoral enhancement is resolved on subsequent imaging but can persist for up to 6 months [15] . The size of the ablated zone remains either stable or progressively decreases as the body removes the zone of induced coagulation and the area undergoes involution. CT scans depicting residual or recurring tumor have shown features such as general enlargement of the ablated region or nodular enhancing masses developing along the margins or near the site of ablation. Other distinctive patterns that have been correlated with tumor are unclear delineation of the margins resulting in a halo appearance and a wide, irregular peripheral enhancing rim distinguished from the adjacent hepatic parenchyma [17] .
Typical MR Imaging Features of RFA
On typical MR imaging, the standard RFA ablation zone may appear to have low signal intensity on T2-weighted images and high signal intensity of T1-weighted images. The hypointensity on T2-weighted images is probably attributed to dehydration and coagulation as a result of the ablation process. If the ablated lesion becomes filled by fibrin or hemorrhage, a hyperintense focus may be detected on T2-weighted images. In certain cases, there is bright signal on T2-weighted imaging and contrast enhancement on T1-weighted imaging surrounding the treated lesion immediately post-treatment and this may occur from an inflammatory response to the thermal injury or reactive hyperemia. However, the fully treated area does not usually enhance on subsequent imaging. On T1-weighted imaging, lesions display heterogeneous signal intensity because necrosis patterns differ among lesions. Compared with the pre-treatment lesion, the post-ablation region is usually larger to encompass a margin of normal tissue but this area involutes over time. On follow-up imaging, recurrent or residual lesions surrounding the ablative zone appear irregular and exhibit moderately high signal intensity on T2-weighted images [18] .
Materials and Methods

Patient Population
We retrospectively reviewed the records of patients with unresectable primary or metastatic liver neoplasms who underwent a Phase I clinical trial combining RFA and LTLD at our institution. Twenty-four patients were enrolled in the trial. Only 17 patients were evaluated because the remaining patients received treatment at another institution and their imaging was not available at the time of evaluation. One of these patients did not have an immediate post-ablation CT scan and was excluded from the analysis, leaving 16 for analysis. Lesion histologies included hepatocellular carcinoma, adenocarcinoma, adrenal cortical carcinoma, colorectal carcinoma, and renal cell carcinoma. Patients who underwent RFA without LTLD served as unmatched controls. These patients were obtained through random selection of the institution's database of patients receiving RFA of a liver lesion without LTLD that had a follow-up CT scan 3-5 weeks later, as well as Phase I patients who had subsequent RFA performed without LTLD.
Procedure
A single dose of LTLD was given intravenously 15 min prior to the RFA, and the carrier liposome deployed doxorubicin at temperatures [39.5°C. RFA was performed using standard algorithms with a commercial 200-W generator and water-cooled electrodes (Covidien, Inc., Boulder, CO). All procedures were performed with patients under general anesthesia. The peri-procedural enhanced CT scan was performed immediately after the completion of treatment.
Dosing of the LTLD was implemented using the patient's body surface area (BSA in m 2 ) and a 3 9 3 dose escalation design with five dose levels: 20, 30, 40, 50, and 60 mg/m 2 .
Imaging Protocol
Serial diagnostic imaging comprised enhanced CT, dynamic contrast-enhanced MRI (DEMRI), and PET before the therapy, immediately post-procedure, at 28 ± 5 days post therapy, and at 3-month intervals (±5 days) for the first year and then at 6-month intervals until evidence of recurrence, administration of additional antitumor treatment, or a total of 3 years. Recurrent hepatic tumors were treated with repeat RFA without LTLD after the Day 28 assessment. Triple-phase CT images were acquired on GE Lightspeed scanners (GE Healthcare, Pewaukee, WI) with Isovue-300 IV contrast. Arterial, venous, portal, and delayed phase images were obtained. MRI images were acquired on 1.5T GE Signa scanners (GE Healthcare, Pewaukee, WI). T1W, T2W pre-contrast, and post-contrast MR images were obtained using gadopentetate dimeglumine (Magnevist, Bayer HealthCare, Montville, NJ) as a contrast agent.
Image Analysis
All imaging scans were analyzed retrospectively by a board-certified radiologist.
Volumetric lesion size was determined on CT images by contouring the index tumors and post-treatment ablation areas on each axial slice (Vitrea, Toshiba Medical Systems, Minnetonka, MN). Penumbras were analyzed from the T1W MRI. Qualitative imaging features on CT were evaluated in terms of rim or margin enhancement characteristics, and the dynamic imaging appearances were described over time.
Case controls for patients receiving liver RFA without LTLD were compared to the study group in terms of ablation zone dynamics in the weeks following ablation.
Data Analysis
Statistical analyses were performed using JMP 9.0 (SAS Institute, Cary, NC). The change in ablation zone volume from peri-procedure imaging was compared between study subjects and controls, and was also compared between subjects receiving low (B40 mg/m 2 ) and high (C50 mg/ m 2 ) doses of LTLD. The presence and/or size of penumbras (regular, smooth, enhancing rim) on T1W MRI were also analyzed. The statistical testing of continuous variables was performed using the two-tailed Wilcoxon/Kruskal-Wallis rank-sum test. Statistical testing of categorical variables was performed using the Fisher's exact test. A significance level of 0.05 was used for all comparisons.
Results
Imaging from 16 patients (10 male, 6 female) in the RFA ? LTLD cohort were analyzed (median age 56.5). Six control cases of standard RFA were also analyzed. Three of these cases of standard RFA were performed in different liver lesions of protocol patients who had previously undergone RFA ? LTLD, and three other patients outside the protocol had undergone standard RFA at our institution (Table 1) .
Qualitatively, the thermal lesion size was larger on contrast-enhanced CT 28 days after the procedure compared to peri-procedural imaging. A smooth enhancing rim was seen on contrast-enhanced CT and dynamic contrast MR imaging at the thermal lesion margin. This rim also showed hypermetabolic activity on PET imaging and regressed over time with a benign appearance.
Tumor Size and Ablated Volumes
The mean and maximum tumor volumes for the study group and control group were 42.6 and 133.7 ml versus 29.0 and 137.4 ml, respectively (Fig. 1) . In one subject in the study group, two adjacent lesions were treated together; tumor size in this patient was considered to be the sum of these volumes.
In the study group, 11 of 16 (69 %) had stable or increased ablation zone sizes on CT at a mean of 29.1 days post RFA (Fig. 2) . Of the control group, 6 of 6 (100 %) had a decrease in ablation zone sizes at a mean of 31.5 days post RFA (p = 0.001). At 1-month follow-up, the ablative zone is in fact larger in the RFA ? LTLD group, and not just less quickly resolving.
At follow-up, the mean volume changes in the study group and the control group were ?4.7 and -7.4 ml, respectively, which were statistically different (p = 0.03). When considering the change in ablation zone volume as a proportion of the peri-procedural ablation zone volume, this corresponded to a significant difference in the mean percentage change of ?26.6 % (median: ?5.9 %) and -19.1 % (median: -15.5 %), respectively (Fig. 3, p = 0.01) .
Within the study group alone, the change in ablative zone volume was not significantly different across dose levels of LTLD (p = 0.65), nor was the percentage change in ablative zone volume (Fig. 4, p = 0.40) .
Imaging Features
Distinctive imaging characteristics were found in the RFA plus LTLD group compared with conventional RFA. It was noted that one patient had a pre-existing tumor penumbra on contrast-enhanced CT and MRI and was excluded from this analysis, and in another the T1-weighted MRI was not well delineated (penumbra was measured on contrast-enhanced CT for subsequent analysis). The follow-up T1-weighted MRI showed a regular, smooth, enhancing rim around the ablative zone in 13 of the remaining 14 cases (Fig. 5) . The mean and maximum volume of this penumbra Index tumor size (Mean ± SD/ml) 42.6 ± 40.5 29.0 ± 53.9
Peri-procedural ablation zone size (mean ± SD/ml) 59.7 ± 43.0 53.0 ± 55.2
Ablation zone size at 1-month follow-up (Mean ± SD/ml) 64.4 ± 43.7 45.6 ± 52.9
Change in ablation zone size ?26.6 ± 59.3 % -19.1 ± 13.0 % Fig. 1 Sizes of index lesions, peri-procedural ablation zones, and ablation zones at 1-month follow-up in the RFA ? LTLD and RFA alone groups was 30.5 and 61.4 ml, respectively. The mean and maximum volume of the penumbra as a percentage of the ablation zone size on follow-up was 53 and 125 %, respectively.
Penumbra Sizes of Low Dose Versus High Dose
At the lower doses of LTLD (B40 mg/m 2 ), the mean and maximum penumbra volume was 30.1 and 61.4 ml (n = 8), respectively. At high doses of LTLD (C50 mg/ m 2 ), the mean and maximum penumbra volume was 30.1 and 48.4 ml, respectively (n = 6). This corresponds to a mean and maximum penumbra volume of 56 and 125 % of the ablated zone in the low-dose subgroup and 48 and 83 % in the high-dose group, respectively (Fig. 6) . Neither the absolute penumbra size (p = 0.75) nor the penumbra size as a percentage of the ablation zone was significantly different between the low-dose and high-dose groups (p = 0.56).
Discussion
Comparison of maximum diameters of ablative zones between the control and study groups immediately post procedure and approximately 1 month post procedure revealed significant differences. The ablative zones of the patients treated with RFA ? LTLD were typically stable or enlarged in the 4 weeks following ablation, in contrast to conventional RFA where the ablative zone decreased in size in the 4 weeks following ablation. The mechanism of the involution has not been elucidated though there are several hypotheses. The involution may be due to stunned hypertrophy of normal liver that is impaired with ongoing cell death from chemotherapeutic mechanisms. The involution may also be attributed to atrophy of the ablated tissue from continuing coagulative necrosis. Ongoing stability or growth of the low-attenuation area of the LTLDtreated area suggests therapeutic effect at the desired Fig. 3 The percentage change in ablative zone volumes at 1-month follow-up from peri-procedural imaging is compared between the control and study groups Fig. 4 The percentage change in ablative zone volumes at 1-month follow-up from peri-procedural imaging is compared between the control group and various dosage levels of LTLD The non-enhancing low-attenuation ablative zone on CT represents coagulation necrosis [19, 20] . The typical characteristics of a recurrent lesion include a wide rim with a nodular and irregular border [21] which is hyperdense on arterial phase [22] . The penumbra of an ablative zone after RFA treatment is often narrow, with a smooth or regular border, and decreases in enhancement over time. The addition of LTLD results in a penumbra that is usually thicker than RFA in the absence of the drug. In one study, mean lesion volumes measured by summation of areas decreased by 21 %, 1 month after RFA, and peripheral rim enhancement on CT resolved in all 34 lesions [23] . The addition of LTLD to RFA resulted in distinctive imaging appearance of a rather wide enhancing rim but with a smooth, regular edge as evidenced by increased attenuation on CT and increased signal on MRI. Moreover, the enhancement of the treatment group appeared to persist for a longer length of time compared to that of the control group. Thus, a radiologist may potentially misinterpret the wide, persistent rim of a post RFA ? LTLD region as a recurrence rather than the proposed drug effect of the LTLD. The wide enhancement seen in the imaging of the LTLD treatment group may correspond to the geometries of predicted maximum drug release at the periphery of the ablation zone, although this is speculative [11] .
This analysis may potentially underestimate the sizes and characteristics of the treatment zone given that the study group was selected from a Phase I dose escalation study and thus 9 out of the 17 sample lesions were treated at drug dosages lower than the standard MTD that would generally be used for treatment. A phase III randomized clinical trial of the RFA and LTLD with doxorubicin using the MTD has been recently completed and the imaging results from this study may yield a more accurate evaluation. These descriptive trends need to be validated in future studies and multi-center trials will further define imaging rules or trends for interpreting radiologists to consider.
The case controls were compiled from a database of patients treated with RFA to the liver at the same institution with the same primary operator, rather than from a prospective cohort. RFA procedures between the two groups may differ due to randomly varying techniques or patient characteristics.
The imaging features following RFA with LTLD are different from standard post-ablative imaging and can be mistaken for residual or recurrent tumor. Growth of the ablative zone after RFA with LTLD suggests ongoing druginduced biological effects and may support a mechanism of action in this drug plus device therapy. Unlike tumor recurrence, this increase in size is expected to regress over time.
Although speculative, the goal is to increase the threshold size indications for this local therapy.
